Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Metrics to compare | ALZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALZNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.5x | −3.1x | −0.6x | |
PEG Ratio | −0.02 | 0.03 | 0.00 | |
Price/Book | 2.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 147.3x | 3.3x | |
Upside (Analyst Target) | - | 156.2% | 37.9% | |
Fair Value Upside | Unlock | −5.1% | 3.7% | Unlock |